Eli Lilly & Co. said Tuesday that it has launched new doses of its obesity treatment drug and reduced its prices. The pharmaceutical company said it has launched 7.5 and 10 milligram single dose vials ...

Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...

Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program.1 Lilly also ...

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses ...

U.S. stock futures (ES00) (NQ00) weakened after the S&P 500 SPX finished at its lowest level since mid-January. Bitcoin (BTCUSD) traded below $90,000, and the yield on the 10-year Treasury declined.

Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at ...

Artificial intelligence models are forecasting a notable rise in Eli Lilly's stock prices. These AI-driven algorithms analyze ...

In this article, we will take a look into Eli Lilly and Co's (NYSE:LLY) DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow as ...

Eli Lilly and Company, Johnson & Johnson, Pfizer, Merck & Co., Inc., and Novo Nordisk A/S are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. These ...

The lawsuit claims the FDA's finding that there was no longer a shortage of the drugs' active ingredient semaglutide was ...

Hims & Hers Health shares plunged in extended trading Monday after the online healthcare provider reported falling margins as costs rose.

Health-care companies rose as traders rotated into defensive sectors.